STA®-Liquid Fib is the lastest innovation in our routine line. This new liquid reagent for the quantitative determination of fibrinogen leve...
As part of Stago's continuous improvement commitment, STA®-ImmunoDef VIII* & STA®-ImmunoDef IX* kits have been developed as a new generation...
As part of Stago's continuous improvement commitment, STA® -Liatest® D-Di Plus* was developed as an evolution of the STA® -Liatest® D-Di, on...
Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. ...
Diagnostica Stago, the worldwide leader in the field of Haemostasis is setting the standard of excellence, with cutting-edge technologies, products and customer service. United Kingdom is one of the countries where research is the most advanced in the field of coagulation and the demand for new technologies is great. In January 2005, the subsidiary Diagnostica Stago UK was opened.
Stago’s first mission is to provide health professionals with reliable, powerful and innovative haemostasis diagnostic tools in looking for a way to improve prevention, understanding, diagnostic, treatment and follow-up of coagulation-related pathologies.
September 3rd - 4th, 2013
September 23rd - 25th, 2013
October 10th - 11th2013
Did you know?
In 1977, with Bjarne Østerud, Dr. S.I. Rapaport described the activation of factor IX by factor VIIa/tissue factor complex as an additional pathway in the initiation of blood coagulation.
We don't have any job openings at the moment. Please check back later.